NLS and Kadimastem move forward with merger plans

Published 31/01/2025, 13:36
© Kadimastem PR

ZURICH and NESS ZIONA, Israel - Shareholders of Kadimastem Ltd. (TASE: KDST), a cell therapy company currently valued at $18.19 million, have approved a merger with Swiss biopharmaceutical firm NLS Pharmaceutics Ltd. (Nasdaq: NLSP), advancing the creation of a combined entity focused on developing therapies for neurodegenerative diseases and diabetes. The announcement follows a special general meeting held on January 30, 2025, where Kadimastem’s shareholders gave their consent to the union. The company’s stock has shown remarkable momentum, delivering a 178% return over the past year, though InvestingPro analysis suggests the stock may be overvalued at its current price of $4.34.

This pivotal decision marks a significant progression in the merger process, which is expected to result in a Nasdaq-traded biotechnology company. Both companies are currently preparing for final approvals, with NLS planning its own shareholder meeting to ratify the merger. According to InvestingPro data, Kadimastem maintains a GOOD overall financial health score despite reporting negative EBITDA of $1.92 million in its latest reporting period.

Ronen Twito, Executive Chairman and CEO of Kadimastem, expressed satisfaction with the shareholder endorsement, anticipating the merger to leverage the joint strengths of both companies in biotechnology. Alex Zwyer, CEO of NLS, echoed these sentiments, highlighting the potential benefits of the combined efforts.

The merger is set to bring together NLS’s experience in central nervous system disorders with Kadimastem’s cell therapy platforms, including AstroRx® for ALS treatment and IsletRx for diabetes. The aim is to address unmet medical needs and enhance value creation for shareholders.

While the companies anticipate the successful completion of the merger, they remain cautious, acknowledging various risks and uncertainties that could impact the process and outcomes. These include the satisfaction of closing conditions, regulatory approvals, and potential market reactions. InvestingPro subscribers can access additional risk metrics and 8 more exclusive ProTips to better evaluate the merger’s potential impact on their investment decisions.

The information provided is based on a press release statement, and further details about the merger will be available through documents filed with the SEC, which can be accessed at www.sec.gov and on the companies’ respective websites.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.